Logo
x

Search

Subscribe Now

adjuvant

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

  • August 23, 2021
GSK and Medicago Initiate P-II/III Study of its Plant-Derived COVID-19 Vaccine

GSK and Medicago Initiate P-II/III Study of its Plant-Derived COVID-19 Vaccine

  • November 13, 2020
AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's Priority Review for the Adjuvant Treatment of Patients with Early-Stage...

  • October 20, 2020
Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treat

Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER...

  • November 15, 2019
Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US

Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in...

  • May 6, 2019
Merck's Keytruda (pembrolizumab) Receives FDA's Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node

Merck's Keytruda (pembrolizumab) Receives FDA's Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymp...

  • February 20, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.